| Rodrigo G. Bristol, M.d., Inc. | |
|
634 Kalihi St Honolulu HI 96819-4000 | |
| (808) 845-3911 | |
| (808) 848-0870 |
| Full Name | Rodrigo G. Bristol, M.d., Inc. |
|---|---|
| Speciality | General Practice |
| Location | 634 Kalihi St, Honolulu, Hawaii |
| Authorized Official Name and Position | Rodrigo Gose Bristol (PRESIDENT) |
| Authorized Official Contact | 8088453911 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Rodrigo G. Bristol, M.d., Inc. 634 Kalihi St Honolulu HI 96819-4000 Ph: (808) 845-3911 | Rodrigo G. Bristol, M.d., Inc. 634 Kalihi St Honolulu HI 96819-4000 Ph: (808) 845-3911 |
| NPI Number | 1053625723 |
|---|---|
| Provider Enumeration Date | 08/04/2010 |
| Last Update Date | 08/04/2010 |
| Medicare PECOS PAC ID | 4284810094 |
|---|---|
| Medicare Enrollment ID | O20110512000055 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.
A large-scale international study has demonstrated the usefulness of a blood test to confirm or exclude the diagnosis of acute heart failure in emergency room patients and shows that the test also can identify patients at a higher risk for death.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053625723 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 2213 (Hawaii) | Primary |
| Provider Name | Rodrigo G Bristol |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1811079924 PECOS PAC ID: 3274719083 Enrollment ID: I20110512000074 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.
A large-scale international study has demonstrated the usefulness of a blood test to confirm or exclude the diagnosis of acute heart failure in emergency room patients and shows that the test also can identify patients at a higher risk for death.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."
› Verified 3 days ago
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.
A large-scale international study has demonstrated the usefulness of a blood test to confirm or exclude the diagnosis of acute heart failure in emergency room patients and shows that the test also can identify patients at a higher risk for death.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."
› Verified 3 days ago
Sbk Medical Consulting Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1441 Kapiolani Blvd Ste 606, Honolulu, HI 96814 Phone: 808-951-9931 | |
Emily Diep, M.d., Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 321 N Kuakini St, Suite Number 715, Honolulu, HI 96817 Phone: 808-523-6461 Fax: 808-550-0466 | |
Restoration Health Care Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 828 18th Ave, Honolulu, HI 96816 Phone: 808-892-7571 | |
Central Medical Clinic Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 321 N. Kuakini St., Suite #201, Honolulu, HI 96817 Phone: 808-523-8611 | |
Frederick Fong Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1380 Lustiana Street, Suite 514, Honolulu, HI 96813 Phone: 808-531-7551 Fax: 808-537-3652 | |
Dr Jin Kim Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2851 E Manoa Rd Ste 1-205, Honolulu, HI 96822 Phone: 808-988-6113 | |
Mahalo Doctor Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 415-314-0699 |